Key Points
- Director Ramiro Guerrero purchased 46,620 MAIA shares at an average of $1.35, investing $62,937 and increasing his direct ownership by 6.77% to 735,701 shares. He also bought additional shares in four transactions earlier in August.
- MAIA shares opened at $1.30, down 0.8%, with a market capitalization of approximately $79.1 million. The stock has traded between $0.87 and $3.19 over the past 12 months.
- The clinical-stage biopharmaceutical company reported a quarterly loss of $0.13 per share, missing analyst expectations of a $0.11 loss; analysts forecast a full-year loss of $0.54 per share.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ramiro Guerrero bought 8,931 shares of the firm's stock in a transaction on Wednesday, August 26th. The shares were acquired at an average cost of $1.39 per share, with a total value of $12,414.09. Following the purchase, the director directly owned 610,842 shares of the company's stock, valued at approximately $849,070.38. This represents a 1.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Ramiro Guerrero also recently made the following trade(s):
- On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.35 per share, for a total transaction of $62,937.00.
- On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.39 per share, for a total transaction of $108,752.21.
- On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.33 per share, with a total value of $2,386.02.
- On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.37 per share, for a total transaction of $16,301.63.
MAIA Biotechnology Price Performance
Shares of NYSEAMERICAN:MAIA opened at $1.30 on Wednesday. The business has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.43. The company has a market capitalization of $79.08 million, a PE ratio of -2.10 and a beta of 0.25. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MAIA Biotechnology
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology in the second quarter worth approximately $29,000. PVG Asset Management Corp purchased a new position in shares of MAIA Biotechnology during the 1st quarter worth $46,000. Susquehanna International Group LLP bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at $51,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth $52,000. Finally, Corsair Capital Management L.P. purchased a new stake in shares of MAIA Biotechnology in the 1st quarter worth $140,000. Hedge funds and other institutional investors own 5.65% of the company's stock.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
